The Radiological Response Rate Pattern Is Associated With Recurrence Free Survival in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

Juneyoung Ahn, Woo-Chan Park, Chang Ik Yoon, Pill Sun Paik, Min Kyung Cho, Tae-Kyung Yoo

Division of Breast Surgery, Department of Surgery, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

ABSTRACT

Purpose: The aim of this study was to evaluate the radiological response rate patterns during neoadjuvant chemotherapy (NAC) in patients with breast cancer.

Methods: Patients who underwent NAC with two specific chemotherapy regimens (doxorubicin with cyclophosphamide or doxorubicin with docetaxel) and who underwent a response evaluation every two cycles were included in the study. The initial response ratio was defined as the ratio of the largest tumor diameter at diagnosis to that after two cycles of NAC. The latter response ratio was defined as the ratio between the tumor size after two cycles and that after four cycles of NAC. The radiological response rate pattern was divided into three groups: the fast-to-slow response group (F–S group, initial response ratio > latter response ratio + 20%), slow-to-fast response group (S–F group, latter response ratio > initial response ratio + 20%), and constant response group (less than 20% difference between the initial and latter response ratios).

Results: In total, 177 patients were included in the analysis. Forty-two (23.9%) patients were categorized into the F–S group, 26 (14.8%) into the S–F group, and 108 (61.2%) into the constant group. Clinicopathologic factors did not differ according to radiologic response rate patterns. The median follow-up period was 50 months (range, 3–112) months. In the univariate analysis, the F–S group had a significantly worse recurrence-free survival than the S–F and constant groups (hazard ratio [HR], 3.63; 95% confidence interval [CI], 1.05–12.46; \( p = 0.041 \)). The F–S group also presented with significantly worse survival than the S–F group in the multivariate analysis (HR, 3.45; 95% CI, 1.00–11.89; \( p = 0.049 \)).

Conclusion: The F–S group had a poorer survival rate than the S–F group. Radiological response rate patterns may be useful for accurate prognostic assessments, especially when considering post-neoadjuvant therapy.

Keywords: Breast Neoplasms; Magnetic Resonance Imaging; Neoadjuvant Therapy; Recurrence; Response Rate
INTRODUCTION

Neoadjuvant chemotherapy (NAC) is the standard treatment for locally advanced breast cancer and is increasingly being used in the treatment of early breast cancer. The primary advantage of NAC is improved surgical outcomes by improving the rate of breast-conserving surgery [1]. Randomized clinical trials have demonstrated no significant differences in the overall survival (OS) or disease progression between patients who underwent adjuvant chemotherapy and NAC [2, 3]. However, response to NAC provides important prognostic information, such as pathologic complete response (pCR), which is related to favorable long-term disease-free survival (DFS) and OS [4]. The frequency of pCR was relatively low; a frequency of 18% was found for ypT0/is ypN0 in a previous meta-analysis [5]. Recent studies have shown higher response rates in human epidermal growth factor receptor 2 (HER2)-positive tumors owing to the development of new targeted therapies [6, 7].

A large proportion of patients with residual disease still lacks surrogate markers for survival. This has become increasingly relevant as adjuvant therapy is currently commonly recommended in patients with residual disease after NAC, especially in triple-negative and HER2-positive breast cancers [8, 9]. Several studies have attempted to develop models to predict the prognosis of patients with post-NAC residual lesions. The yp-stage from the American Joint Committee on Cancer (AJCC) and residual cancer burden (RCB) are the two main methods used to evaluate residual disease in pathologic resection specimens [10, 11]. The preoperative endocrine prognostic index score also uses post-treatment pathology results for the individualization of adjuvant therapy in patients undergoing neoadjuvant endocrine therapy [12].

Breast magnetic resonance imaging (MRI) is the most accurate imaging modality for the assessment of tumor response to NAC [13, 14]. Several studies have demonstrated that an early change in tumor size, observed via MRI, during NAC is an effective tool for predicting tumor response [15-17]. Yu et al. [15] evaluated magnetic resonance images of patients who underwent NAC with doxorubicin and cyclophosphamide (AC), followed by a taxane regimen after the first cycle. They found that an early change in tumor size observed on MRI was highly predictive of the final response. A small study by Padhani et al. [17] also demonstrated that tumor size reduction was the best early predictor of tumor response.

Here, we investigated whether the pattern of tumor size reduction on breast MRI was related to NAC response and patient survival.

METHODS

Breast cancer patients who underwent NAC at Seoul St. Mary’s Hospital between 2010 and 2017 were retrospectively reviewed. The inclusion criteria were as follows: 1) patients who were treated with two specific chemotherapeutic regimens (doxorubicin and docetaxel [AT] or AC) were included to assess the temporal change in tumor response without change in chemotherapeutic agents; and 2) patients who underwent a response evaluation using breast MRI every two cycles were included to accurately assess the tumor size. Patients with metastatic breast cancer, occult breast cancer, or those who had undergone incomplete NAC treatment for any cause were excluded (Figure 1). HER2-targeted therapy was only administered as adjuvant therapy to patients with HER2-positive tumors.
The tumor shrinkage rate was calculated using the change in the largest tumor diameter between the two cycles observed via breast MRI. The initial response ratio was calculated by comparing the tumor size at diagnosis with that after two cycles of chemotherapy. The latter response ratio was calculated by comparing the tumor size after two cycles to that after four cycles of chemotherapy.

\[
\text{Initial Response Ratio} = \frac{\text{Pre-NAC Tumor Size} - \text{Post 2 NAC Tumor Size}}{\text{Pre NAC Tumor Size}} \times 100
\]

\[
\text{Latter Response Ratio} = \frac{\text{Post 2 NAC Tumor Size} - \text{Post 4 NAC Tumor Size}}{\text{Post 2 NAC Tumor Size}} \times 100
\]

The radiologic response rate was classified into three groups using the initial and latter response ratios. A patient was classified into the fast-to-slow response group (F–S group) when the initial response ratio was greater than 20% compared with the latter response ratio, indicating that the tumor size decreased more in the first two cycles. On the other hand, patients were classified into the slow-to-fast response group (S–F group) when the tumor size decreased more in the latter two cycles, with a difference of more than 20%. Patients with less than a 20% difference between the two ratios were assigned to the constant group (Figures 2 and 3).

Pathologic factors such as histologic type, grade, hormone receptor status, HER2 status, and Ki-67 were primarily extracted from core needle biopsy pathology reports. When these factors were missing, data were obtained from surgical specimen pathology reports. Tumor, Node, Metastasis (TNM) staging was performed according to the 7th edition of the AJCC on Cancer staging system.
Recurrence-free survival (RFS) and OS were estimated using the Kaplan–Meier test, with statistical significance based on the log-rank test. The RFS was calculated from the date of breast cancer diagnosis to locoregional recurrence, contralateral breast recurrence, or distant metastasis. OS was defined as the time from diagnosis to death due to any cause. Cox regression analysis of the association between RFS and radiologic response groups was performed using univariate and multivariate analyses, including prognostic pathologic factors. All analyses were performed using Statistical Package for the Social Sciences version 24 (IBM Corporation, Armonk, USA).

This study was approved by the Institutional Review Board of Seoul St. Mary’s Hospital (IRB No. KC20RISI0684). The requirement for informed consent was waived.

RESULTS

Between 2010 and 2017, 396 patients with breast cancer underwent NAC at Seoul St. Mary’s Hospital. Among them, 176 (44.4%) patients treated with concurrent chemotherapy (AC or AT) and who were evaluated every two cycles using breast MRI were included. A total of 114

Figure 2. The three groups of radiologic response rate patterns. (A) Fast-to-slow group, (B) Constant group, and (C) Slow-to-fast group.
Among the 176 patients, 42 (23.9%) showed a fast-to-slow response, 26 (14.8%) presented with a slow-to-fast response, and 108 (61.2%) were categorized into the constant group. The mean age of the patients was 47 years (range, 21–69). Of these patients, 83 (47.2%) had stage 2 tumors and 93 (52.8%) had stage 3 tumors. The hormone receptor status was positive in 111 patients (63.1%). The NAC responses were as follows: pCR, 18 (10.2%) patients; partial response, 118 (67.0%) patients; stable disease, 38 (21.6%) patients; and progressive disease, 2 (1.1%) patients. The radiologic response rate pattern was not related to the pCR rate ($p = 0.160$). Additionally, no significant differences were observed in the clinicopathological factors according to the radiologic response rate. However, a non-significant but higher Ki-67 index was found in the F–S group than in the constant or S–F groups ($p = 0.056$).

The median follow-up period was 50 months (range, 3–112). The five-year OS and RFS rates were 93.2% and 76.7%, respectively. RFS was significantly worse in the F–S response group than in the constant and S–F groups (log-rank test, $p = 0.044$; hazard ratio [HR], 3.63; 95% confidence interval [CI], 1.05–12.46; Figure 4A and Table 2). However, the OS did not differ between the groups ($p = 0.368$; Figure 4B). After adjusting for prognostic factors that were significant for RFS in the univariate analysis, the F–S response group still presented with worse outcomes than the constant and S–F groups (HR, 3.45; 95% CI, 1.00–11.89; $p = 0.049$; Table 2). However, significance was only seen between the S and F and F–S groups, whereas the S–F and constant groups showed no significant difference (HR, 1.92; 95% CI, 0.57–6.42; $p = 0.289$).
Radiological Response Pattern of Patients With Neoadjuvant Chemotherapy

Table 1. Clinicopathologic characteristics according to radiologic response pattern groups

| Characteristics          | Fast-to-Slow | Constant | Slow-to-Fast | p-value |
|--------------------------|--------------|----------|--------------|---------|
| No. of patients          | 42 (23.9)    | 108 (61.4) | 26 (14.8)    |         |
| Age (yr)                 |              |          |              | 0.443   |
| < 50                     | 27 (64.3)    | 59 (54.6) | 13 (50.0)    |         |
| ≥ 50                     | 15 (35.7)    | 49 (45.4) | 13 (50.0)    |         |
| Breast surgery           |              |          |              | 0.986   |
| BCS                      | 17 (40.5)    | 43 (39.8) | 10 (38.5)    |         |
| TM                       | 25 (59.5)    | 65 (60.2) | 16 (61.5)    |         |
| Axillary surgery         |              |          |              | 0.080   |
| SLNB                     | 5 (11.9)     | 31 (28.7) | 5 (19.2)     |         |
| ALND                     | 37 (88.1)    | 77 (71.3) | 21 (80.8)    |         |
| Clinical T stage         |              |          |              | 0.481   |
| cT1-2                    | 29 (69.0)    | 67 (62.0) | 19 (73.1)    |         |
| cT3-4                    | 13 (31.0)    | 41 (38.0) | 7 (26.9)     |         |
| Clinical N stage         |              |          |              | 0.142   |
| cNo-1                    | 26 (61.9)    | 83 (76.9) | 17 (65.4)    |         |
| cN2-3                    | 16 (38.1)    | 25 (23.1) | 9 (34.6)     |         |
| TNM Stage                |              |          |              | 0.944   |
| II                       | 19 (45.2)    | 52 (48.1) | 12 (46.2)    |         |
| III                      | 23 (54.8)    | 56 (51.9) | 14 (53.8)    |         |
| ypT/NM stage             |              |          |              | 0.189   |
| I                        | 8 (19.0)     | 25 (23.1) | 6 (23.1)     |         |
| II                       | 17 (40.5)    | 56 (51.9) | 10 (38.5)    |         |
| III                      | 11 (26.2)    | 23 (21.3) | 7 (26.9)     |         |
| Histologic subtype       |              |          |              | 0.025   |
| IDCa                     | 31 (73.8)    | 96 (88.9) | 26 (100)     |         |
| ILCa                     | 3 (7.1)      | 5 (4.6)   | 0 (0.0)      |         |
| Others                   | 8 (19.0)     | 7 (6.5)   | 0 (0.0)      |         |
| Histologic grade         |              |          |              | 0.147   |
| 1–2                      | 26 (61.9)    | 76 (70.4) | 22 (84.6)    |         |
| 3                        | 16 (38.1)    | 32 (29.6) | 4 (15.4)     |         |
| Subtype                  |              |          |              | 0.131   |
| Luminal                  | 19 (45.2)    | 73 (67.6) | 19 (73.1)    |         |
| HER2                     | 11 (26.2)    | 14 (13.0) | 3 (11.5)     |         |
| TNBC                     | 16 (38.1)    | 32 (29.6) | 4 (15.4)     |         |
| Unknown                  | 0 (0.0)      | 1 (0.9)   | 0 (0.0)      |         |
| Ki-67 (%)                |              |          |              | 0.056   |
| < 20                     | 17 (40.5)    | 61 (56.5) | 18 (69.2)    |         |
| ≥ 20                     | 25 (59.5)    | 47 (43.5) | 8 (30.8)     |         |
| Unknown                  | 1 (2.4)      | 2 (1.9)   | 2 (7.7)      |         |
| Pathological response    |              |          |              | 0.160   |
| pCR                      | 4 (9.5)      | 4 (3.7)   | 3 (11.5)     |         |
| Non pCR                  | 38 (90.5)    | 104 (96.3)| 23 (88.5)    |         |
| Clinical response        |              |          |              | 0.014   |
| CR                       | 8 (19.0)     | 8 (7.4)   | 2 (7.7)      |         |
| PR                       | 25 (59.5)    | 70 (64.8) | 22 (84.6)    |         |
| SD                       | 7 (16.7)     | 30 (27.8) | 2 (7.7)      |         |
| PD                       | 2 (4.8)      | 0 (0.0)   | 0 (0.0)      |         |
| Neoadjuvant chemotherapy regimen |         |          |              | 0.044   |
| AC                       | 7 (16.7)     | 40 (37.0) | 7 (26.9)     |         |
| AT                       | 35 (83.3)    | 68 (63.0) | 19 (73.1)    |         |

Values are presented as number of patients (%).

BCS = breast-conserving surgery; TM = total mastectomy; SLNB = sentinel lymph node biopsy; ALND = axillary lymph node dissection; IDCa = infiltrative ductal carcinoma; ILCa = invasive lobular carcinoma; HER2 = human epidermal growth factor receptor 2; TNBC = triple-negative breast cancer; pCR = pathological complete response; CR = complete response; PR = partial response; SD = stable disease; PD = progressive disease; NAC = neoadjuvant chemotherapy; AC = doxorubicin and cyclophosphamide; AT = doxorubicin and taxane.
Table 2. Univariate and multivariate analyses of clinicopathologic factors and recurrence-free survival

| Clinicopathologic factors        | Univariate analysis | Multivariate analysis |
|----------------------------------|---------------------|-----------------------|
|                                  | Hazard ratio        | 95% CI                | p-value | Hazard ratio | 95% CI                | p-value |
| Age (yr)                         |                     |                       |         |             |                       |         |
| < 50                             | 1 (reference)       |                       |         | 1 (reference) |                       |         |
| ≥ 50                             | 1.64                | 0.89–3.04             | 0.113   | 2.19        | 1.17–4.11             | 0.014   |
| cT stage                         |                     |                       |         |             |                       |         |
| 1–2                              | 1 (reference)       |                       |         | 1 (reference) |                       |         |
| 3–4                              | 2.15                | 1.15–4.02             | 0.016   | 2.19        | 1.17–4.11             | 0.014   |
| cN stage                         |                     |                       |         |             |                       |         |
| 0                                | 1 (reference)       |                       |         | 1 (reference) |                       |         |
| 1–3                              | 8.61                | 1.18–62.85            | 0.034   | 2.26        | 1.20–4.26             | 0.011   |
| Histologic grade                 |                     |                       |         |             |                       |         |
| 1–2                              | 1 (reference)       |                       |         | 1 (reference) |                       |         |
| 3                                | 1.84                | 0.99–3.44             | 0.053   |             |                       |         |
| Hormone receptor                 |                     |                       |         |             |                       |         |
| Positive                         | 1 (reference)       |                       |         | 1 (reference) |                       |         |
| Negative                         | 1.47                | 0.80–2.73             | 0.219   |             |                       |         |
| HER2                             |                     |                       |         |             |                       |         |
| Positive                         | 1 (reference)       |                       |         | 1 (reference) |                       |         |
| Negative                         | 0.74                | 0.41–1.36             | 0.333   |             |                       |         |
| Ki-67 (%)                        |                     |                       |         |             |                       |         |
| < 20                             | 1 (reference)       |                       |         | 1 (reference) |                       |         |
| ≥ 20                             | 1.92                | 0.86–2.10             | 0.153   |             |                       |         |
| Radiologic response group        |                     |                       |         |             |                       |         |
| S-F group                        | 1 (reference)       |                       |         | 1 (reference) |                       |         |
| F-S group                        | 3.63                | 1.05–12.46            | 0.047   | 3.45        | 1.00–11.89            | 0.049   |
| Constant group                   | 1.92                | 0.57–6.42             | 0.289   | 2.02        | 0.60–6.82             | 0.255   |
| Chemotherapy clinical response   |                     |                       |         |             |                       |         |
| CR                               | 1 (reference)       |                       |         |             |                       |         |
| PR                               | 0.92                | 0.32–2.66             | 0.888   |             |                       |         |
| SD                               | 1.14                | 0.35–3.66             | 0.821   |             |                       |         |
| PD                               | 5.02                | 0.55–45.43            | 0.151   |             |                       |         |

CI = confidence interval; HER2 = human epidermal growth factor receptor 2; S-F = slow-to-fast; F-S = fast-to-slow; CR = complete response; PR = partial response; SD = stable disease; PD = progressive disease.

Figure 4. Kaplan–Meier curve of RFS and OS by radiologic response rate pattern group. (A) RFS by radiologic response rate pattern group. (B) OS by radiologic response rate pattern group. RFS = recurrence-free survival; OS = overall survival; HR = hazard ratio; CI = confidence interval.
DISCUSSION

In this study, we evaluated the pattern of tumor shrinkage during NAC in patients with breast cancer and investigated the association between size reduction rate and patient outcome. The radiologic response rate pattern showed no association with the pCR rate. However, the recurrence rate was higher in the F–S group than that in the S–F group. This means that a tumor with a slower size reduction rate during the latter cycles of neoadjuvant therapy has a higher recurrence rate than tumors that reduce consistently or faster during treatment.

Our study is the first to explore the significance of radiologic response rate patterns based on tumor size observed on MRI in breast cancer patients undergoing NAC. A tumor that reduces more slowly as therapy proceeds may indicate that tumor resistance develops during treatment, leading to a higher recurrence rate. This assumption is relevant, as all patients included in this study received two specific regimens (AT or AC) that did not change chemotherapy agents during the treatment period. Molecular studies on breast cancer have demonstrated the presence of molecular heterogeneity not only between subtypes but also within each subtype at the individual tumor level [18,19]. These results imply that even the same cancer subtype can elicit different responses to therapy. At the intratumor level, some tumor cells die, but others repopulate during treatment.

Our results can be partly explained by tumor heterogeneity and selective pressure. When selective pressure, such as chemotherapy, is administered, the treatment-sensitive portion of a tumor is eliminated, while the resistant portion survives and expands [20]. Chemotherapy also induces new genomic, transcriptomic, and epigenetic aberrations at the subclonal level, which leads to resistance. The reduced tumor shrinkage rate in the F–S group can be interpreted as treatment resistance, which leads to a higher recurrence rate.

The response to NAC varied among individuals. Molecular subtype, clinical stage, and treatment regimen can affect the response to NAC [21,22]. Currently, the classification by breast cancer stage after NAC is based on the AJCC on Cancer classification system. The system is based on the size of the tumor (T), number of positive lymph nodes (N), and existence of distant metastases (M). This system only applies to the final tumor size and has no specific correlation with prognosis. However, a more accurate prediction of the prognosis of NAC-treated patients can lead to an appropriate adjuvant therapy plan, avoiding overtreatment, which may cause harm to patients and unnecessary medical costs. Our study suggests that radiologic response rate patterns can contribute to the prediction of the prognosis of residual lesions.

The need for an additional prognostic factor to predict residual disease after NAC has been acknowledged by other groups who have presented various evaluation methods. The RCB index was developed to quantify residual disease and consists of the primary tumor bed diameter, ratio between the size of the primary tumor and that in residual invasive cancer, number of positive lymph nodes, and size of the largest metastatic lymph node [10]. The RCB index is a prognostic factor for long-term survival after NAC and has been used in clinical trials to evaluate the outcomes of residual disease after NAC [23]. Matsubara et al. [24] reported that a high reduction in Ki-67 after NAC is related to a favorable prognosis, similar to that of patients with pCR. Additionally, the tumor response ratio, calculated from the tumor size on pre-NAC imaging and residual tumor size, has been demonstrated to be a more accurate assessment of prognosis than pathologic staging [25].
However, the cut-off value for each radiologic response rate group is controversial. The difference between the initial and latter response ratios is a critical value in this study, and we suggest 20% as the standard cut-off value. No specific reference for the optimal cut-off value currently exists. We additionally analyzed the cases using different cutoff values, such as 15% and 30%, but the 20% cutoff value provided the best significance, which was the reason we adopted this value. To the best of our knowledge, no previous study has assessed the relationship between tumor size reduction patterns and prognosis. Further studies with larger sample sizes might set a standard and provide better support for certain cutoff values.

This study has some limitations. First, this was a retrospective, single-center study with a small sample size. Second, the duration of NAC was relatively short and consisted of only four or six cycles of chemotherapy. Additionally, even for patients who underwent six cycles of chemotherapy, the MRI images obtained after two and four cycles were used to evaluate tumor response. This was chosen so that we could compare the tumor response at identical time points for patients who underwent four cycles. However, assessing tumor response before the completion of NAC is a limitation. Third, HER2-targeted therapies were not used in the patients with HER2-amplified breast cancer. The lack of long-term follow-up data is also a limitation as breast cancer has a chance of late recurrence. Multivariate analysis showed no significant correlation between radiologic response pattern groups and RFS, but the F–S group tended to have a worse prognosis. Our small sample size may be one reason for this tendency. Therefore, further studies with larger populations are needed to provide statistically significant results before generalizing the trends observed in our study.

In conclusion, we demonstrated that certain patterns can be observed for reduction in tumor size during NAC in breast cancer. A slower reduction in tumor size as treatment proceeds presents with a poorer prognosis than consistent or faster reductions in tumor size during treatment. Further studies should be conducted with larger cohorts and longer follow-up periods to reproduce these results, which may help in the proper management of post-NAC residual lesions.

REFERENCES

1. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001;96:102.

2. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005;97:188-94.

3. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001;19:4224-37.

4. Kong X, Moran MS, Zhang N, Haffty B, Yang Q. Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer 2011;47:2084-90.

5. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014;384:364-72.
6. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:25-32. 

PUBMED | CROSSREF

7. Schneeweiss A, Chia S, Hickish T, Harvey V, Emie A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013;24:2278-84. 

PUBMED | CROSSREF

8. Masuda N, Lee SI, Ohtani S, Im YH, Lee ES, Yokota I, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 2017;376:2147-59. 

PUBMED | CROSSREF

9. von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 2019;380:617-28. 

PUBMED | CROSSREF

10. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007;25:4414-22. 

PUBMED | CROSSREF

11. Gabriel NH, Carl JD, Stephen BE, Elizabeth AM, Hope SR, et al. Breast. In: Mahul BA, editor. American Joint Committee on Cancer (AJCC). AJCC Cancer Staging Manual. 8th ed. New York: Springer International Publishing.

12. Ellis MJ, Tao Y, Luo J, A’Hern R, Evans DB, Bhatnagar AS, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008;100:1380-8. 

PUBMED | CROSSREF

13. Fowler AM, Mankoff DA, Joe BN. Imaging neoadjuvant therapy response in breast cancer. Radiology 2017;285:358-75. 

PUBMED | CROSSREF

14. Dialani V, Chadashvili T, Slanetz PJ. Role of imaging in neoadjuvant therapy for breast cancer. Ann Surg Oncol 2015;22:1416-24. 

PUBMED | CROSSREF

15. Yu HJ, Chen JH, Mehta RS, Nalcioglu O, Su MY. MRI measurements of tumor size and pharmacokinetic parameters as early predictors of response in breast cancer patients undergoing neoadjuvant anthracycline chemotherapy. J Magn Reson Imaging 2007;26:615-23. 

PUBMED | CROSSREF

16. Cheung YC, Chen SC, Su MY, See LC, Hsueh S, Chang HK, et al. Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI. Breast Cancer Res Treat 2003;78:51-8. 

PUBMED | CROSSREF

17. Padhani AR, Hayes C, Assersohn L, Powles T, Makris A, Suckling J, et al. Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. Radiology 2006;239:361-74. 

PUBMED | CROSSREF

18. Joseph C, Papadaki A, Althobiti M, Alsalem M, Aleskandarany MA, Rakha EA. Breast cancer intratumour heterogeneity: current status and clinical implications. Histopathology 2018;73:717-31. 

PUBMED | CROSSREF

19. Aleskandarany MA, Vandenberghe ME, Marchiò C, Ellis IO, Sapino A, Rakha EA. Tumour heterogeneity of breast cancer: from morphology to personalised medicine. Pathobiology 2018;85:23-34. 

PUBMED | CROSSREF

20. Mavrommati I, Johnson F, Echeverria GV, Nattrajan R. Subclonal heterogeneity and evolution in breast cancer. NPJ Breast Cancer 2021;7:155. 

PUBMED | CROSSREF

21. Haque W, Verma V, Hatch S, Suzanne Klimberg V, Brian Butler E, Teh BS. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy. Breast Cancer Res Treat 2018;170:559-67. 

PUBMED | CROSSREF

22. Mamounas EP, Anderson SJ, Dignam JJ, Bear HD, Julian TB, Geyer CE Jr, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol 2012;30:3060-6. 

PUBMED | CROSSREF

https://ejbc.kr

https://doi.org/10.4048/jbc.2022.25.e19
23. Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, et al. Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. J Clin Oncol 2017;35:1049-60.

PUBMED | CROSSREF

24. Matsubara N, Mukai H, Masumoto M, Sasaki M, Naito Y, Fujii S, et al. Survival outcome and reduction rate of Ki-67 between pre- and post-neoadjuvant chemotherapy in breast cancer patients with non-pCR. Breast Cancer Res Treat 2014;147:95-102.

PUBMED | CROSSREF

25. Miller M, Ottesen RA, Niland JC, Kruper L, Chen SL, Vito C. Tumor response ratio predicts overall survival in breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol 2014;21:3317-23.

PUBMED | CROSSREF